



## Early View

Research letter

# The Prevalence and Burden of Interstitial Lung Diseases in the United States

Niranjan Jeganathan, Matheni Sathananthan

Please cite this article as: Jeganathan N, Sathananthan M. The Prevalence and Burden of Interstitial Lung Diseases in the United States. *ERJ Open Res* 2021; in press (<https://doi.org/10.1183/23120541.00630-2021>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

# **The Prevalence and Burden of Interstitial Lung Diseases in the United States**

Niranjan Jeganathan MD, MS, Matheni Sathanathan MD

## **Corresponding Author:**

Niranjan Jeganathan MD, MS  
Department of Medicine  
Division of Pulmonary, Critical Care, Hyperbaric, Allergy and Sleep Medicine  
Loma Linda University Health  
11234 Anderson Street, Room 6424  
Loma Linda, CA 92354  
[njeganathan@llu.edu](mailto:njeganathan@llu.edu)

## **Author Affiliations:**

Matheni Sathanathan, MD: Department of Medicine, Loma Linda University Health, Loma Linda, CA, 92354

**Prior publication/presentation:** The authors attest that this manuscript is not under consideration for publication elsewhere. No aspect of this manuscript has been published elsewhere. No aspect of this study was previously presented.

**Competing interests:** No potential conflicts of interest to disclose for Drs. Jeganathan and Sathanathan

**Financial/nonfinancial disclosures:** none to disclose for Drs. Jeganathan and Sathanathan

**Take home message:** Interstitial lung diseases (ILD) are a significant contributor to disability and deaths in the U.S. The prevalence and deaths from ILD have increased, but when adjusted for age have been stable since 2010.

## **To the Editor:**

Interstitial lung diseases (ILDs) are a heterogeneous group of diseases (i.e. idiopathic interstitial pneumonia, autoimmune ILDs, environmental exposure-related ILDs, sarcoidosis) but share several common clinical and pathophysiological features [1, 2]. ILDs are associated with significant morbidity, mortality and increased financial burden [3, 4].

In the last two decades, there has been significant progress in the diagnosis and treatment of ILDs. However, comprehensive epidemiological data remains limited. Since mortality rates do not give a complete picture of the burden of disease, the World Health Organization assesses the overall burden of disease using DALYs, a time-based measure that combines years of life lost due to premature mortality and years of healthy life lost due to disability. The objective of this study is to report current estimates and trends of ILD prevalence, disability-adjusted life years (DALYs), and deaths in the U.S.

## **Materials and Methods**

The data for this study was derived from the Global Burden of Disease (GBD) 2019 study published by the Institute for Health Metrics and Evaluation. The methods used in this study have previously been reported in detail [5]. In brief, the GBD study analyzes epidemiologic data uses statistical modeling and provide estimates of disease prevalence and burden. This research study is a secondary analysis of the GBD study results. Data were obtained from the Global Health Data Exchange online tool (<http://ghdx.healthdata.org/gbd-results-tool>). The abbreviation ILD used in our study refers to combined data of both ILD and pulmonary sarcoidosis. We extracted the crude and age-standardized rates from 2010-2019 stratified by sex and age group. Age-standardized rates were based on the GBD global reference population.

## **Results**

In 2019, in the U.S., there was an estimated 654,841 (95% UI 566,536-745,855) cases of ILD, 429,786 (95% UI 283,468-505,372) DALYs and 21,505 (95% UI 12,237-26,667) deaths from ILD.

In 2019, the crude prevalence of ILD per 100,000 was 179.7 in males and 218.9 in females (Table 1). The age-standardized prevalence of ILD per 100,000 was 121.3 (95% UI 105.7-136.5) in males and 131.4 (95% UI 114.8-148.3) in females. The overall crude prevalence increased 19.1% from 2010 to 2019, however, the age-standardized prevalence rate was stable.

In 2019, the crude DALY rate from ILD per 100,000 was 142.4 in males and 118.2 in females. The age-standardized ILD DALY rate per 100,000 was 93.3 (95% UI 58.9-110.3) in males and 69.3 (95% UI 45.1-82.2) in females. The overall

crude DALY rate increased 15.8% from 2010 to 2019 (21% in males and 10.2% in females). The age-standardized DALY rates have been stable since 2010.

In 2019, the crude death rate from ILD per 100,000 was 7.3 in males and 5.9 in females. The age-standardized death rate from ILD per 100,000 was 4.6 (95% UI 2.5-5.7) in males and 2.9 (95% UI 1.5-3.6) in females. The crude death rates increased 18.1% compared to 2010. The percent increase was higher in males compared to females (25.7% vs. 10.2%). The age-standardized death rates were stable.

In 2019, the crude and age-standardized case fatality rates in males were 4.0% (95% UI 2.6-4.4) and 3.8% (95% UI 2.4-4.2) respectively. In females, the crude and age-standardized case fatality rates were 2.7% (95% UI 1.5-3.0) and 2.2% (95% UI 1.3-2.5) respectively.

The age-specific prevalence of ILD was noted to increase with increasing age, reaching the highest prevalence in the 80-84 year age group. In 2019, the prevalence in this age group per 100,000 in males was 1,167 and in females was 983.5. The ILD prevalence was slightly lower in males until age 75 years and was higher compared to females in those over age 75 years. The age-specific DALY rates and death rates also increased with increasing age in both males and females. However, the increase in DALY rates and death rates were proportionally higher in males compared to females and therefore the difference widened with increasing age (not shown).

Table 1. Prevalence, Disability-Adjusted Life Year (DALY) and Mortality Rates due to Interstitial Lung Diseases in the United States

	Prevalence (95% UI)			DALY Rates (95% UI)			Mortality Rates (95% UI)		
	2010	2019	Change, %	2010	2019	Change, %	2010	2019	Change, %
<b>Overall</b>	167.7 (151.0 to 183.7)	199.7 (172.7 to 227.4)	19.1 (12.1 to 26.1)	112.4 (75.7 to 132.0)	130.1 (86.4 to 154.1)	15.8 (11.5 to 20.2)	5.5 (3.3 to 6.7)	6.6 (3.7 to 8.1)	18.1 (13.0 to 23.6)
<b>Sex</b>									
Male	147.4 (132.8 to 161.4)	179.7 (155.1 to 205.0)	21.9 (14.7 to 29.2)	117.7 (74.7 to 137.8)	142.4 (88.1 to 169.2)	21.0 (14.7 to 27.3)	5.8 (3.2 to 6.9)	7.3 (4.0 to 9.0)	25.7 (18.0 to 33.2)
Female	187.4 (169.1 to 204.8)	218.9 (189.4 to 249.1)	16.8 (10.0 to 24.3)	107.3 (67.7 to 128.4)	118.2 (74.2 to 141.8)	10.2 (5.8 to 14.7)	5.3 (2.6 to 6.6)	5.9 (2.9 to 7.4)	10.2 (4.5 to 15.5)
<b>Age (years)</b>									
50-54	192.7 (143.7 to 247.6)	197.1 (134.8 to 272.5)	2.3 (-9.1 to 15.0)	103.2 (77.2 to 122.2)	99.5 (74.6 to 117.6)	-3.6 (-9.7 to 2.5)	2.2 (1.6 to 2.5)	2.1 (1.5 to 2.5)	-4.7 (-11.6 to 1.1)
55-59	254.2 (195.5 to 330.0)	262.4 (186.5 to 367.5)	3.2 (-8.9 to 15.9)	148.0 (106.3 to 173.8)	147.5 (105.6 to 177.6)	-0.3 (-6.5 to 5.7)	3.8 (2.5 to 4.3)	3.7 (2.5 to 4.4)	-0.8 (-7.3 to 5.7)
60-64	340.3 (257.5 to 453.8)	357.5 (255.0 to 504.3)	5.1 (-6.4 to 16.2)	221.8 (153.5 to 257.8)	224.6 (155.8 to 264.7)	1.3 (-4.9 to 7.7)	6.7 (4.3 to 7.7)	6.8 (4.4 to 7.9)	0.7 (-5.6 to 8.0)
65-69	464.6 (345.3 to 604.9)	500.5 (345.9 to 696.0)	7.7 (-6.4 to 20.9)	336.9 (216.8 to 397.4)	339.1 (219.8 to 404.6)	0.7 (-5.1 to 6.0)	12.4 (7.5 to 14.5)	12.4 (7.4 to 14.7)	-0.2 (-6.0 to 5.5)
70-74	645.0 (482.8 to 854.1)	694.7 (481.0 to 985.1)	7.7 (-5.2 to 22.1)	486.9 (301.4 to 584.1)	503.9 (308.0 to 614.0)	3.5 (-2.3 to 10.0)	22.2 (12.7 to 26.4)	22.9 (12.7 to 28.1)	3.0 (-3.4 to 10.2)
75-79	844.1 (649.6 to 1085.2)	909.9 (655.9 to 1245.3)	7.8 (-3.4 to 20.7)	639.2 (389.1 to 778.4)	654.2 (392.7 to 810.0)	2.4 (-2.8 to 8.3)	37.1 (20.7 to 45.1)	37.7 (20.8 to 47.1)	1.8 (-3.9 to 8.3)
80-84	981.0 (785.7 to 1189.4)	1061.5 (788.3 to 1398.8)	8.2 (-4.6 to 21.7)	730.1 (430.9 to 912.1)	759.5 (437.6 to 980.3)	4.0 (-2.0 to 11.5)	55.3 (29.5 to 69.7)	57.3 (29.6 to 75.2)	3.6 (-3.3 to 12.4)
>85	929.7 (784.2 to 1072.2)	993.2 (797.2 to 1202.4)	6.8 (-1.7 to 15.3)	719.2 (403.5 to 937.5)	747.4 (399.8 to 991.7)	3.9 (-2.7 to 11.1)	82.1 (41.0 to 109.4)	87.6 (41.2 to 120.1)	6.7 (-2.0 to 15.5)

The prevalence, DALYs, and deaths are presented as crude rates per 100,000 people with corresponding 95% uncertainty intervals (UIs). These were based on 1000 runs of the models for each quantity of interest, with the mean considered as the point estimate, and the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles considered as the 95% UI. All ages were included for the overall rates, and male and female rates.

Non-fatal estimates were obtained from systematic reviews, surveys, administrative health records, registries, and disease surveillance systems. The specific data sources used for quantifying non-fatal outcomes are available online in the GBD Results Tool [6]. Non-fatal data were analyzed using DisMod-MR version 2.1, a Bayesian meta-regression tool that adjusts data points for variations in study methods among different data sources.

Fatal estimates were obtained from vital registration data (death records from the National Center for Health Statistics and population counts from the U.S. Census Bureau). The single cause of death was determined using the *International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification*. Causes of death data were analyzed using the Cause of Death Ensemble Model with corrections for changes in coding practices for underlying causes of death [7].

DALYs were calculated as the sum of years of life lost (YLL) and years of healthy life lost due to disability (YLD) for each cause. For each disease, the YLD is derived from the multiplication of the incidence by the duration of disability and a weight factor. To account for the co-occurrence of disease and injury outcomes, the YLD was corrected for comorbidity, assuming a multiplicative rather than additive function of disability weights. The YLL due to premature death was estimated by multiplying the death number for a given age and sex by the standard life expectancy. One DALY is equal to the loss of one year of healthy life from the combined impacts of death and disability.

Since our study utilized existing data without patient identifiers, it did not require institutional review board approval. The GBD study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) recommendations.

## Discussion

In this study we provide a comprehensive report of the overall prevalence, burden, and trends of ILD in the U.S. Our study shows that ILD remains a significant cause of death and disability in the U.S. In 2019, ILD was present in 0.21% of the population and contributed to 0.39% of the total DALYs and 0.73% of the total deaths. Since 2010 the crude prevalence, DALY rates and death rates of ILD in the U.S. have been increasing, but the age-standardized rates have been stable. Crude rates are reflective of the present disease state and are useful for policymakers and physicians, whereas age-standardized estimates allow comparison over time, adjusting for the differences in the age distribution of the population. This finding suggests that the increase in overall prevalence is primarily due to the increasing average age in the U.S. population. Since smoking is a risk factor for IPF and several other ILDs, the decline in smoking rates in the U.S. likely played a significant role in the stable age-standardized prevalence that was noted [8].

In our study, when stratified by age and gender, the prevalence of ILD was similar for males and females until age 75 years. However, in those older than age 75 years, the prevalence trended toward higher rates in males than females. In addition, the DALYs and deaths seem to increase at a proportionally higher rate for males compared to females over the age of 65 years. This is likely due to a higher percentage of IPF patients among the older age group of ILD patients [9, 10]. In 2019, according to the CDC Wonder Underlying Cause of Death Database [11], the crude mortality rate from pulmonary fibrosis per 100,000 was 5.1 (95% CI 5.0-5.2) in males and 3.7 (95% CI 3.6-3.8) in females. Based on this, pulmonary fibrosis contributed to 69.8% of the ILD deaths in males and 62.7% in females. The percentage of ILD decedents with pulmonary fibrosis increased with age and was 59.4%, 74.2%, and 79.4% in the 65-74 years age group, 75-84 years age group, and those 85 years and older respectively (not shown).

The general limitations of the GBD study have been reported previously [7]. The limitations of our study include variability in the case definitions used to report ILD, leading to potential misdiagnosis and under-diagnosis. The majority of data used to estimate prevalence is derived from hospital records and insurance claims which can be unreliable. Attributable risk factor analysis is not currently available for ILD in the GBD data. The underlying etiology of ILD and stratification based on race are also not available in this data set.

This study provides comprehensive national estimates of the prevalence, mortality, and DALYs due to ILD. Although age-standardized ILD morbidity and mortality have remained stable in the U.S., the ILD ranking as the cause of death and DALYs has worsened. Among the level 3 causes, ILD was ranked as 54<sup>th</sup> in DALYs in 2019, 58<sup>th</sup> in 2010, and 74<sup>th</sup> in 1990. Similarly, ILD was ranked 30<sup>th</sup> among causes of deaths in 2019, compared to 32<sup>nd</sup> in 2010, and 41<sup>st</sup> in 1990 [6].

This suggests that the allocation of resources to understand the risk factors for ILD and to address the burden of disease remains inadequate. Increasing the awareness of the disease, expanding the availability of diagnostic equipment in less-developed areas, and improving access to ILD specialized centers are crucial for early diagnosis and intervention.

## References

1. Cottin, V., et al., *Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases*. Eur Respir Rev, 2018. **27**(150).
2. Cottin, V., et al., *Fibrosing interstitial lung diseases: knowns and unknowns*. Eur Respir Rev, 2019. **28**(151).
3. Frank, A.L., M. Kreuter, and L. Schwarzkopf, *Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care*. Respir Med, 2019. **152**: p. 25-31.
4. Fan, Y., et al., *Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry*. Chest, 2020. **157**(6): p. 1522-1530.
5. Collaborators, G.B.D.C.R.D., *Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017*. Lancet Respir Med, 2020. **8**(6): p. 585-596.
6. *Global Health Data Exchange. GBD results tool*.
7. Diseases, G.B.D. and C. Injuries, *Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019*. Lancet, 2020. **396**(10258): p. 1204-1222.
8. Prevention, C.f.D.C.a., *Current cigarette smoking among adults-United States Morbidity and Mortality Weekly Report 2018*. **67**(44): p. 1225-32.
9. Fernandez Perez, E.R., *Changing trends in age-adjusted pulmonary fibrosis mortality in the USA: a joinpoint regression analysis*. Eur Respir J, 2019. **54**(1).
10. Jeganathan, N., R.A. Smith, and M. Sathananthan, *Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017*. Chest, 2020.
11. Wonder, C. *Underlying Cause of Death 1999 - 2019*. June 25, 2021].